期刊文献+

噻托溴铵雾化吸入溶液在三种口喉模型中的沉积行为 被引量:1

In vitro Deposition Behaviors of Tiotropium Bromide Inhalation Solution in Three Mouth-throat Models
原文传递
导出
摘要 考察了噻托溴铵雾化吸入溶液经振动网式雾化器雾化形成的雾粒在3种口喉模型中的体外沉积行为。口喉模型种类、吸入气流模式及口喉模型内涂层等因素均影响雾粒在口喉模型中的沉积。在15和30 L/min下,噻托溴铵雾粒在理想口喉中的沉积量显著高于中国药典喉和美国药典喉;在模拟呼吸气流模式下的沉积量与15 L/min连续吸入气流模式相近,与30和60 L/min连续吸入气流模式差异显著;在有涂层口喉中的沉积量大于无涂层口喉。联用理想口喉模型和呼吸模拟器组成体外评价装置,可能更适于雾化吸入溶液的体外评价。 The in vitro deposition behavior of tiotropium inhalation solution after atomized by a vibrating-mesh nebulizer was investigated with three mouth-throat models. The mouth-throat models, patterns of inhalation airflow and inner coating on the models could significantly influence the deposition. The amount of tiotropium bromide deposited in idealized mouth-throat model was significantly higher than in Chinese pharmacopeia throat and USP (United States pharmacopeia) mouth-throat (induction port) when tested at continuous airflow of 15 and 30 L/min. The amount of deposition under breath simulator condition was similar to that under continuous airflow of 15 L/min, but was significantly different from middle and high speed (30 and 60 L/min) of continuous airflow patterns. The inner coating on idealized mouth-throat model could increase the tiotropium bromide deposition. A new in vitro evaluation apparatus might be designed by combination of the idealized mouth-throat model and breath simulator, which might be suitable for the in vitro evaluation of inhalation solutions.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第7期677-680,共4页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项(2012ZX09304-004)
关键词 噻托溴铵 雾化吸入溶液 体外评价 理想口喉模型 呼吸模拟器 tiotropium bromide inhalation solution in vitro evaluation idealized mouth-throat model breathsimulator
  • 相关文献

参考文献10

  • 1National Institute of Health, National Heart, Lung, andBlood Institute. Morbidity and mortality: 2007 chart bookon cardiovascular, lung and blood diseases [M]. Bethesda:National Institutes of Health, 2007: 65-76.
  • 2Simpson CR, Hippisley-Cox J, Sheikh A. Trends in theepidemiology of chronic obstructive pulmonary disease inEngland: a national study of 51 804 patients [J]. Br J GenPract, 2010,60(576): 277-284.
  • 3Anderson PJ. History of aerosol therapy: liquid nebulizationto MDIs to DPIs [J]. Respir Care, 2005, 50 (9): 1139-1150.
  • 4Newman S. Respiratory drug delivery: essential theory &practice [M]. River Grove: Davis healthcare internationalpublishing, 2009: 1-356.
  • 5王伟,王健,王浩.噻托溴铵雾化吸入溶液的制备及体外评价[J].中国医药工业杂志,2012,43(4):268-272. 被引量:5
  • 6Mitchell J,Newman S,Chan HK. In vitro and in vivo aspectsof cascade impactor tests and inhaler performance: a review[J]. AAPSPharmSciTech, 2007,8 (4): El 10.
  • 7Zhang Y, Gilbertson K, Finlay WH. In vivo-in vitrocomparison of deposition in three mouth-throat models withQvar and Turbuhaler inhalers [J]. J Aerosol Med, 2007,20 (3):227-235.
  • 8Vecellio L, Kippax P, Rouquette S, et al. Influence of realisticairflow rate on aerosol generation by nebulizers [J]. Int JPharm, 2009, 371 (1-2): 99-105.
  • 9Smaldone G, Solomita M. Predicting in vivo deposition invitro [J]. J Aerosol Med Pulm Drug Deliv, 2009,22 (1):9-10.
  • 10Zhang Y, Finlay WH. Experimental measurements of particledeposition in three proximal lung bifurcation models withan idealized mouth-throat [J]. J Aerosol Med, 2005, 18(4):460-473.

二级参考文献8

  • 1陈桂良,侯惠民.吸入用气雾剂雾粒测定方法的评价[J].中国医药工业杂志,2007,38(3):194-199. 被引量:24
  • 2Cazzola M,Donner CF,Hanania NA. One hundred years of chronic obstructive pulmonary disease (COPD)[J].Respiratory Medicine,2007,(06):1049-1065.
  • 3Bateman ED,Rennard S,Barnes PJ. Alternative mechanisms for tiotropium[J].Pulmonary Pharmacology and Therapeutics,2009,(06):533-542.
  • 4Brashier B,Dhembare P,Jantikar A. Tiotropium administered by a pressurized metered dose inhaler (pMDI)and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD[J].Respiratory Medicine,2007,(12):2464-2471.doi:10.1016/j.rmed.2007.07.006.
  • 5Ghazanfari T,Elhissi AM,Ding Z. The influence of fluid physicochemical properties on vibrating-mesh nebulization[J].International Journal of Pharmaceutics,2007,(03):103-111.
  • 6Louey MD,Razia S,Stewart PJ. Influence of physicochemical carrier properties on the in vitro aerosol deposition from interactive mixtures[J].International Journal of Pharmaceutics,2003,(1-2):87-98.
  • 7Harris JA,Stein SW,Myrdal PB. Evaluation of the TSI aerosol impactor 3306/3321 system using a redesigned impactor stage with solution and suspension metered-dose inhalers[J].AAPS PHARMSCITECH,2006,(01):E20.
  • 8Mitchell JP,Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers:their uses and limitations[J].JAerosol Med,2003,(04):341-377.

共引文献4

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部